Study of adebrelimab for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well adebrelimab works and how safe it is in real-world settings for people with advanced small cell lung cancer that has spread. It may help doctors understand if this treatment is a good option for patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced small cell lung cancer that has spread (extensive-stage).
- You are 18 years or older.
- Your doctor decides you can have or are already taking adebrelimab.
- You are not currently taking other immune-modulating drugs.
- You are not in another interventional study.
- You do not have another type of cancer.
- Your key medical records are complete.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a drug called adebrelimab (a type of immunotherapy) before surgery for people with early-stage small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests a combination of two drugs, adebrelimab and irinotecan liposome, with or without a third drug called famitinib, for people with extensive-stage small cell lung cancer that has progressed after initial treatment with immunotherapy. The goal is to see if this combination can help control the cancer.
This study tests a type of immunotherapy called adebrelimab (a medicine that helps your immune system attack cancer) either alone or with other treatments in people with advanced solid tumors, including small cell lung cancer. The goal is to see if this approach can help control the cancer or improve outcomes.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
This trial tests whether continuing a drug called adebrelimab (an immunotherapy) after standard treatment helps keep limited-stage small cell lung cancer from coming back. It compares adebrelimab with the usual approach of just watching and following up.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy and radiation for limited-stage small cell lung cancer. After the initial treatment, the drug is continued to help keep the cancer from coming back.
Hear when a new Small Cell Lung Cancer (SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.